PMID- 27449721
OWN - NLM
STAT- MEDLINE
DCOM- 20170227
LR  - 20210504
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 15
IP  - 10
DP  - 2016 Oct
TI  - Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the 
      treatment of patients with type 2 diabetes mellitus.
PG  - 1401-12
LID - 10.1080/14740338.2016.1216100 [doi]
AB  - INTRODUCTION: The safety profile of sodium-glucose cotransporter 2 (SGLT2) 
      inhibitors has continued to evolve with the availability of data from clinical 
      trial programs, post-marketing pharmacovigilance and dedicated cardiovascular 
      outcome trials. AREAS COVERED: This article reviews the safety issues associated 
      with the SGLT2 inhibitors canagliflozin, dapagliflozin, and empagliflozin, 
      particularly the newer/emergent safety data related to US Food and Drug 
      Administration statements regarding these three agents. EXPERT OPINION: The 
      safety profile of SGLT2 inhibitors is well defined, and the adverse event profile 
      is largely consistent with their mechanism of action. These well-recognized 
      events include genital mycotic infections and volume-associated adverse events. 
      Serious safety issues detected more recently with SGLT2 inhibitor therapy, such 
      as bone fractures, pyelonephritis, urosepsis, and ketoacidosis, have been 
      uncommon. A robust improvement in cardiovascular outcomes in patients with type 2 
      diabetes mellitus (T2DM) was recently demonstrated with empagliflozin. Given the 
      glucose-lowering efficacy, low risk of hypoglycemia, and other benefits 
      associated with SGLT2 inhibitor therapy, this class of oral glucose-lowering 
      medication is a valuable addition to treatment options for T2DM, and may play an 
      increasingly prominent therapeutic role as emerging data are revealed.
FAU - Carlson, Curt J
AU  - Carlson CJ
AD  - a Lloyd L. Gregory School of Pharmacy , Palm Beach Atlantic University , West 
      Palm Beach , FL , USA.
FAU - Santamarina, Marile L
AU  - Santamarina ML
AD  - a Lloyd L. Gregory School of Pharmacy , Palm Beach Atlantic University , West 
      Palm Beach , FL , USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160812
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Blood Glucose)
RN  - 0 (Glucosides)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (SLC5A2 protein, human)
RN  - 0 (Sodium-Glucose Transporter 2)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0SAC974Z85 (Canagliflozin)
RN  - 1ULL0QJ8UC (dapagliflozin)
RN  - HDC1R2M35U (empagliflozin)
SB  - IM
MH  - Benzhydryl Compounds/adverse effects/pharmacology/therapeutic use
MH  - Blood Glucose/drug effects
MH  - Canagliflozin/adverse effects/pharmacology/therapeutic use
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Glucosides/adverse effects/pharmacology/therapeutic use
MH  - Humans
MH  - Hypoglycemia/chemically induced
MH  - Hypoglycemic Agents/adverse effects/pharmacology/*therapeutic use
MH  - Sodium-Glucose Transporter 2
MH  - *Sodium-Glucose Transporter 2 Inhibitors
OTO - NOTNLM
OT  - Canagliflozin
OT  - dapagliflozin
OT  - empagliflozin
OT  - safety
OT  - sodium-glucose cotransporter 2 inhibitors
OT  - tolerability
OT  - type 2 diabetes mellitus
EDAT- 2016/07/28 06:00
MHDA- 2017/02/28 06:00
CRDT- 2016/07/25 06:00
PHST- 2016/07/25 06:00 [entrez]
PHST- 2016/07/28 06:00 [pubmed]
PHST- 2017/02/28 06:00 [medline]
AID - 10.1080/14740338.2016.1216100 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2016 Oct;15(10):1401-12. doi: 
      10.1080/14740338.2016.1216100. Epub 2016 Aug 12.